TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Consensus Target Price from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $40.67.

TGTX has been the subject of several recent analyst reports. The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,358 shares of company stock valued at $781,497 over the last three months. 10.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TGTX. Rhumbline Advisers raised its position in TG Therapeutics by 7.8% in the second quarter. Rhumbline Advisers now owns 215,055 shares of the biopharmaceutical company’s stock worth $3,826,000 after acquiring an additional 15,582 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of TG Therapeutics by 24.6% in the second quarter. Victory Capital Management Inc. now owns 26,212 shares of the biopharmaceutical company’s stock valued at $466,000 after buying an additional 5,169 shares in the last quarter. Arizona State Retirement System increased its position in shares of TG Therapeutics by 3.9% in the second quarter. Arizona State Retirement System now owns 41,069 shares of the biopharmaceutical company’s stock valued at $731,000 after buying an additional 1,539 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the second quarter valued at $35,000. Finally, Headlands Technologies LLC purchased a new position in shares of TG Therapeutics in the second quarter valued at $124,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $29.55 on Tuesday. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The company has a market cap of $4.60 billion, a PE ratio of -295.47 and a beta of 2.24. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business has a 50-day simple moving average of $31.71 and a 200-day simple moving average of $25.91.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.73 EPS. On average, equities research analysts forecast that TG Therapeutics will post 0.07 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.